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Key points
† Haemodilution with
volume expanders has
agent-specific effects on
coagulation.
† The effects of
haemodilution with
balanced saline,
hydroxyethyl starch, and
gelatin on clot formation
in vitro were investigated
in normal blood.
† Using two independent
assays of clot
viscoelasticity (ROTEMTM
and SONOCLOTTM), both
colloids had significantly
greater negative effects
on coagulation than
balanced saline.
Background. Hydroxyethyl starch (HES) solutions compromise blood coagulation. Low
molecular weight, low-substituted HES products, and electrolyte-balanced solutions
might reduce this effect. We compared the effects of in vitro haemodilution on blood
coagulation with a balanced 6% HES 130/0.42 solution (HESBAL), a saline-based 6% HES
130/0.4 solution (HESSAL), a balanced lactated Ringer’s solution (RL) and a saline-based
4% gelatin solution (GEL).
Methods. Blood was obtained from 10 healthy male volunteers and diluted with the test
solutions by 33% and 66%. Quality of clot formation was measured using two viscoelastic
coagulation tests: SONOCLOTTM and activated rotation thromboelastometry ROTEMTM.
Results. Of 16 parameters measured by the viscoelastic devices, we found three statistically
significant differences compared with baseline for RL, but 11 for GEL, 10 for HESSAL, and 11 for
HESBAL in the 33% haemodilution group (P¼0.01). Comparing the different solutions, we
observed a significant difference between crystalloids and colloids but none between GEL
and HES. In the 66% dilution group, effects on blood coagulation were increased when
compared with the 33% dilution group. We found no differences in coagulation impairment
between balanced and non-balanced HES products and no differences in the detection of
impaired blood coagulation due to haemodilution between the two viscoelastic
coagulation tests.
Conclusions. Both ROTEMTM and SONOCLOTTM are sensitive tests for the detection of impaired
blood coagulation due to haemodilution. There are fewer effects on blood coagulation using
crystalloids compared with colloids. The effects of GEL and HES are similar. There is no
difference between balanced HES 130/0.42 and non-balanced HES 130/0.4.
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During major surgery, administration of synthetic plasma
expanders protects the patient from adverse effects of allo-
geneic blood transfusions such as transmission of infectious
diseases, increases in mortality, major morbidity, transfusion-
related acute lung injury, nosocomial infections, increased
costs, and immunological effects, including tumour growth
promotion.1 – 6 Colloids and crystalloids influence blood
coagulation in different ways. With increasing use, an
additional influence on coagulation by the artificial plasma
expander itself might become clinically relevant beyond the
effect that coagulation factors and platelets are diluted.
In vivo and in vitro, crystalloids show less effect on blood
coagulation than colloids, gelatin shows less effect than
hydroxyethyl starch (HES), and dextrans show the greatest
negative coagulation impact of the colloids.7 – 11 Third-
generation 6% HES 130/0.4 with a lower molecular weight
and a lower molar substitution shows a significantly
reduced negative impact on blood coagulation in vivo and
in vitro compared with early HES products.12 – 14 In addition,
some studies suggest less coagulation impairment by HES
†Poster presentation at the Annual Meeting of the American Society of Anesthesiologists (ASA) 2008.
‡ These authors contributed equally to the study.
British Journal of Anaesthesia 105 (3): 273–81 (2010)
Advance Access publication 21 July 2010 . doi:10.1093/bja/aeq173
& The Author [2010]. Published by Oxford University Press on behalf of the British Journal of Anaesthesia. All rights reserved.
For Permissions, please email: journals.permissions@oxfordjournal.org
preparation in a balanced solution with physiological,
plasma-adapted electrolyte concentrations.15 16
The purpose of this study was to assess the effects of
in vitro haemodilution on blood coagulation of commonly
used volume expanders: 6% HES in a balanced 130/0.42
and non-balanced 130/0.4 solution compared with 4%
gelatin solution, and a balanced Ringer’s lactate-crystalloid
solution. Apart from standard coagulation variables, we
assessed the quality of clot formation using two different
viscoelastic devices, SONOCLOTTM and ROTEMTM. In addition,
we evaluated and compared these two point-of-care devices.
Methods
After approval by the institutional ethics committee (Kantonale
Ethik-Kommission des Kantons Luzern, protocol number 686)
and written informed consent, 10 healthy volunteers (28–52
yr of age) were enrolled. Inclusion criteria for the study were
male sex, no history of chronic or acute diseases, no intake of
any medication, in particular acetylsalicylic acid or non-
steroidal anti-inflammatory agents within 2 weeks before the
study, no alcohol or drug abuse, or smoking. Blood samples
were obtained from an antecubital vein using an 18 G venous
cannula (VasofixTM, B. Braun, Melsungen, Germany). To
exclude blood coagulation activation due to venous stasis,
vein puncture, or blood withdrawal, we discarded 5 ml of
native blood (whole blood) before 2 ml of native blood for
SONOCLOTTM analysis and 4 ml of citrated blood for thromboe-
lastometry were taken for each measurement. The different
plasma expander solutions were immediately diluted using
polystyrene tubes and the coagulation measurements started
within 2 min after having obtained the blood sample. After
measurement of an undiluted sample, the blood was diluted
33% and 66% by volume (as in former investigations with
similar interrogations),8 9 12 16 using as test solutions: an elec-
trolyte plasma-adapted, ‘balanced’ Ringer’s solution (contain-
ing Na+ 140 mM, Cl2 127 mM, K+ 4.0 mM, Ca2+ 2.5 mM, Mg2+
1.0 mM, acetate 24.0 mM, and malate 5.0 mM, Ringerfundin
TM
,
B. Braun), a conventional saline-based 4% gelatin solution (con-
taining Na+ 154 mM and Cl2120 mM,Gel 4%
TM
, B. Braun), a con-
ventional, non-balanced 6% HES 130/0.4/9:1 solution
(6%¼concentration/130 kDa¼mean molecular weight/
0.4¼molar substitution ratio, the average number of hydro-
xyethyl groups per unit of glucose/9:1¼C2:C6 ratio, the distri-
bution of the hydroxyethyl units between the C2 and C6
positions of the glucose unit) containing Na+ 154 mM and Cl2
154 mM, Voluven
TM
, Fresenius Kabi, Bad Homburg, Germany),
and a balanced 6% HES 130/0.42/6:1 solution, based on
potato as the biological source (containing Na+ 140 mM, Cl2
118 mM, K+ 4.0 mM, Ca2+ 2.5 mM, Mg2+ 1.0 mM, acetate 24.0
mM, and malate 5.0 mM, Tetraspan 6%
TM
, B. Braun).
Routine laboratory tests were done with the automated ana-
lysing systems at the central laboratory. All blood samples for
routine laboratory tests were obtained at once, whereas
native blood samples for SONOCLOTTM and citrated blood
samples for ROTEMTM had to be obtained with an 18 G venous
cannula shortly before processing. The dilutions were prepared
as mentioned above and the following parameters were ana-
lysed: haematocrit, haemoglobin concentration, platelet
count, fibrinogen, activated partial thromboplastin time (aPTT)
and prothrombin time (PT) with international normalized ratio.
To rule out a platelet defect, we used the Platelet Function
Analyzer PFA-100TM (Dade/Behring, Marburg, Germany) and
investigated the initial steps of platelet-mediated blood
coagulation using ADP and epinephrine stimulation.17
Analysis of clot formation was performed with two whole-
blood coagulation tests: SONOCLOTTM (Sonoclot II Coagulation
and Platelet Function Analyzer, Sienco Co., Morrison, CO, USA)
and activated rotation thromboelastometry (ROTEMTM, Penta-
pharm, Munich, Germany). The principle of these tests is the
analysis and graphical presentation of changes in viscoelastic
properties of clot formation and retraction and subsequent
fibrinolysis. The tests are sensitive to impairment of clot for-
mation involving coagulation factors and inhibitors, platelets,
and fibrinogen. Technical details of the two coagulation ana-
lysers and their parameters have been described previously.18
SONOCLOTTM
To accelerate the coagulation process, the cuvette contains
5 mg of Celite to activate factor XII at the beginning of the
intrinsic pathway. As determined in other SONOCLOTTM-
based trials,8 19 we evaluated the following parameters: acti-
vated clotting time (ACT), clot rate (CR), peak amplitude (PA),
and time to peak (TTP). ACT is the time from test start until
the beginning of fibrin formation and corresponds to the con-
ventionally measured ACT. Fibrin formation (Gel phase) starts
when the viscosity of the sample begins to increase by fibrin
formation from fibrinogen and is characterized by the
primary slope of the curve (CR). After completion of clot for-
mation, PA reflects the fibrinogen concentration. TTP charac-
terizes clot retraction and describes the speed and quality of
fibrin formation8 18 – 20 (Fig. 1).
ROTEMTM
Citrated-anticoagulated blood (0.3 ml) was re-calcified with
20 ml calcium chloride. Activation of coagulation was per-
formed as follows: extrinsic thromboelastometry (Extem)
with 20 ml of tissue thromboplastin, intrinsic thromboelasto-
metry (Intem) with 20ml of the surface activator partial throm-
boplastin, and native thromboelastometry (Natem) without
activator, only with re-calcification. We determined the follow-
ing parameters: onset of coagulation [coagulation time (CT)],
kinetics of clot formation [clot formation time (CFT): the time
elapsed between 2 and 20 mm clot firmness], the Alpha
angle (angle of a tangent to the clotting curve through the
2 mm point), and maximum clot firmness (MCF). All measure-
ments were performed within 2 min after blood withdrawal at
378C using reagents from the manufacturer (Fig. 2).
Statistical analysis
Statistical analysis was done using the commercially avail-
able software package Statistica Version 7.0 (StatSoft Inc.,
Tulsa, OK, USA) and StatExact 7.0 (Cytel Software
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Corporation, Cambridge, MA, USA). Non-parametric analysis
was performed with one-way analysis of variance (ANOVA)
equivalent test procedure with multiple testing and pair
characteristic of the data; post hoc comparison with the Bon-
ferroni correction was applied to adjust the level of signifi-
cance. Subsequently, the Fisher–Freeman–Halton test was
applied to analyse the categorical data of inhomogeneous
distribution of the coagulation tests by haemodilution.
Because of the obvious effect of the two dilutional steps,
the statistical differences are not shown. Of further interest
are the differences between the solutions at their various
levels of dilution. Data are mean (SD). A P-value ,0.05 was
considered statistically significant.
Results
Ten volunteers with a median body weight (range) of 78 (70–
86) kg and body height of 181 (175–187) cm were enrolled.
All baseline values including PT, aPTT, fibrinogen,
haematocrit, haemoglobin concentration, and platelet
count were within the normal range. Platelet dysfunction
was excluded by normal PFA measurements (ADP- and
epinephrine-closure time) (Table 1). After dilution, fibrinogen,
haematocrit, haemoglobin concentration, and platelet count
decreased, and PT and aPTT increased, indicating compro-
mised blood coagulation (data not shown). Furthermore, all
baseline variables measured by SONOCLOTTM and ROTEMTM
were within normal limits as defined by the manufacturers.
SONOCLOTTM
After haemodilution, ACT and TTP were prolonged and CR
and PA decreased, representing the negative influence of
dilution on haemostasis.
33% haemodilution. Compared with baseline, ACT showed
a significant prolongation for all agents. Additionally, CR
decreased and TTP increased for all colloids (Table 2).
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Fig 1 (A) Normal SONOCLOTTM curve. (B) SONOCLOTTM curve after 66% haemodilution with balanced-electrolyte lactated Ringer’s solution (RL).
ACT, activated clotting time; CR, clot rate; PA, peak amplitude; TTP, time to peak.
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66% haemodilution. ACT increased and CR decreased sig-
nificantly compared with baseline regarding all agents.
TTP increased significantly for all colloids compared with
baseline (Table 3).
ROTEMTM
After haemodilution, CT was prolonged, Alpha angle and MCF
decreased, and CFT increased.
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Fig 2 (A) Normal Extem ROTEMTM curve. (B) Extem ROTEMTM curve
after 66% haemodilution with balanced-electrolyte lactated
Ringer’s solution (RL). CT, coagulation time; CFT, clotting for-
mation time; MCF, maximum clot firmness.
Table 1 Baseline coagulation and platelet variables of the 10
volunteers. ADP, adenosine diphosphate; aPTT, activated partial
thromboplastin time; Hb, haemoglobin; Hct, haematocrit; INR,
international normalized ratio; PFA, platelet function analyzer; PT,
prothrombin time; SD, standard deviation
Mean (SD) Range
Platelet count (103 ml21) 220 (41) 175–289
Hb (g l21) 153 (10) 140–172
Hct (%) 43 (3) 40–49
Fibrinogen (g l21) 2.5 (0.5) 1.8–3.4
PT (%) 98 (10) 85–118
INR 1.03 (0.05) 0.95–1.10
aPTT (s) 30 (2) 28–32
PFA 100-closure time (s)
ADP 88 (12) 65–110
Epinephrine 141 (30) 106–205
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33% haemodilution. Extem-CT was significantly prolonged
compared with baseline only for HESBAL. We found a sig-
nificant Extem-CFT increase and Extem-Alpha decrease
between baseline and after dilution by colloids.
Extem-MCF decreased significantly for all agents. The col-
loids showed a significant Intem-CFT increase and
Intem-Alpha decrease compared with baseline. All
agents showed a significant decrease in Intem-MCF com-
pared with baseline. Natem-CT was only significantly pro-
longed between GEL and baseline. Natem-MCF showed a
significant decrease to baseline for the colloids (Table 2).
66% haemodilution. In Extem-CT, we found a significant
prolongation between baseline and HES products. All
agents significantly increased Extem-CFT and decreased
Extem-Alpha and Extem-MCF compared with baseline.
All agents were significantly different from baseline in
the Intem measurements (increase in CT and CFT and
decrease in Alpha and MCF). In Natem-CT, a significant
prolongation was only observed between baseline and
HESBAL. Natem-CFT significantly increased and
Natem-Alpha and Natem-MCF decreased between base-
line and all agents (Table 3).
Summarized results of SONOCLOTTM and ROTEMTM
We compared the number of significant differences in
SONOCLOTTM- and ROTEMTM-parameters (a total of 16
values). We found three statistical significant differences
compared with baseline values for RL, 11 for GEL, 10 for
HESSAL, and 11 for HESBAL (Table 2). The Fisher–Freeman–
Halton test showed a significant difference between the
agents listed in Table 2 (P,0.01). There were no significant
differences between the agents in the Freeman–Halton
test for the 66% haemodilution group (Table 3). The inter-
group analysis showed a pronounced reduction of blood
coagulation by the use of colloids compared with crystalloids
in both dilution groups (33% and 66%) (Tables A1 and A2).
SONOCLOTTM vs ROTEMTM and vs haematological
parameters
Baseline haematological laboratory values were correlated
with the readout variables of SONOCLOTTM (ACT, CR, PA, and
TTP) and ROTEMTM (CT, CFT, and MCF with the activation
paths Extem, Intem, and Natem). A statistically significant
correlation was found between fibrinogen level and
Intem-MCF (r¼0.79) and between platelet count and
Natem-MCF (r¼0.73). No correlation could be found
between ACT and Extem-, Intem-, or Natem-CT. CR correlated
significantly with Extem-CT (r¼0.66) and Intem-CFT
(r¼0.74). TTP also correlated significantly with Intem-CT
(r¼0.66) and Intem-MCF (r¼0.83). The MCF values as
measured with the Extem and Natem activation paths of
ROTEMTM also correlated but not with Intem-MCF value. CF
correlated significantly with TTP (r¼0.64) but only with
Intem-CFT (r¼0.74). When using a cluster analysis, ACT can
most suitably be linked to Extem-CFT and Intem-CFT.
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Discussion
We found a pronounced inhibitory effect of colloids com-
pared with crystalloids on blood coagulation after 33% hae-
modilution in vitro. There were no differences in the effects
on blood coagulation between the gelatin solution and
both HES products, or between the balanced- and the saline-
based HES solutions. There was no difference between the
colloids in the 66% haemodilution groups. The intergroup
comparisons confirmed the pronounced reduction of blood
coagulation by the use of colloids compared with crystalloids
in both dilution groups.
Intravascular volume expanders inhibit blood coagulation
concentration dependently. A mild-to-moderate haemodilu-
tion with crystalloids can accelerate blood coagulation
in vitro8 9 and in vivo.21 – 23 An imbalance between decreased
antithrombin III activity and thrombin generation can partly
explain this effect.21 In contrast, the use of colloids for hae-
modilution leads to compromised blood coagulation as
shown in most studies. Gelatin solutions might influence
the weight and reticular network of fibrin strands and plate-
let function by ristocetin and polybrene with decreased von
Willebrand factor.24 25 However, other studies have shown
only a moderate effect9 26 or indicate that blood coagulation
might even be accelerated.8 11 HES compromises blood
coagulation significantly as in vitro8 9 12 13 and in vivo
studies have shown.11 27 28 There are several mechanisms
which influence blood coagulation, for example, an acquired
von Willebrand syndrome and decreasing effect on factor
VIII and decreased expression and activation of platelet
surface GPIIb–IIIa receptor with impaired platelet adhesion
and aggregation.13 14 A further mechanism appears to be the
impaired polymerization of fibrin monomers by HES macro-
molecules.11 13 In addition to the quantity of the adminis-
tered HES, the chemical properties of the molecules play an
important role in blood coagulation. A high molecular
weight seems to be of minor importance compared with a
high molar substitution.29 A reduction of the C2/C6 ratio
results in faster HES elimination without influence on blood
coagulation.30 Low molecular weight, low-substituted 6%
HES 130/0.4 possesses a lower molecular weight and a
lower molar substitution, and many trials have observed
less negative impact on blood coagulation compared with
early HES products.12 – 14 31 32 When HES is prepared in a
balanced solution with physiological electrolyte concen-
trations, impaired coagulation is reduced.15 16 33
We did not find evidence for hypercoagulation during hae-
modilution with crystalloids. All measured coagulation par-
ameters remained unchanged or showed a tendency
towards a hypocoagulable condition. Although balanced
Ringer’s solution should theoretically compromise coagu-
lation only to a low extent due to the additional calcium
ions, we could not confirm this hypothesis. The ROTEMTM
device is not suitable for such examinations as the citrated
blood samples are re-calcified resulting in a surplus of
calcium ions in the sample. In contrast to the ROTEMTM
device, SONOCLOTTM only uses native blood samples and
does not need additional calcium. But, there is no indication
of a minor influence of balanced volume expanders on hae-
modilution compared with saline-based volume expanders in
the SONOCLOTTM measurements either.
Furthermore, we did not observe significant differences
between balanced and non-balanced HES products. Balanced
solutions do not possess high and unphysiological concen-
trations of sodium and chloride (each 154 mM) as saline-
based volume expanders do. Therefore, the risk of developing
a hyperchloraemic acidosis after administration of large
amounts of such solutions is decreased.34 35 Boldt and col-
leagues36 reported no differences between balanced 6% HES
130/0.42 together with a balanced crystalloid solution and
non-balanced 6% HES 130/0.42 together with an unbalanced
saline solution in an in vivo study. They found no differences
between the two groups regarding Intem-CT, Intem-CFT,
and Intem-MCF at baseline and at postoperative day 1. In a
follow-up in vitro study, Boldt and colleagues described a
more negative effect on coagulation using non-balanced 6%
HES 130/0.4 compared with balanced 6% HES 130/0.42. In
the 50% dilution group, they found more pronounced
changes in Intem-MCF, Intem-CFT, Extem-CT, Extem-CFT,
and Extem-MCF when using the non-balanced solution com-
pared with the balanced solution, whereas in the 30% dilution
group, changes were found in Extem-CFT and Extem-CT.16 As
mentioned above, ROTEMTM is not a suitable device for exam-
ining the difference between a balanced and a non-balanced
volume expander by an in vitro test. In contrast, in our study,
we performed an additional viscoelastic coagulation assess-
ment and evaluated a total of 16 test parameters of both
the ROTEMTM and the SONOCLOTTM devices.
For both viscoelastic devices, a high sensitivity is required
to identify a haemodilution coagulopathy. ACT, CR, and TTP
seem to be sensitive parameters for detecting haemodilution
coagulopathies of the SONOCLOTTM analysis, whereas ACT is
the most sensitive of all parameters (providing statistical sig-
nificant results for all tested agents in our study). Regarding
the ROTEMTM analysis, CFT, Alpha, and MCF are sensitive par-
ameters with MCF as the most sensitive one. Extem and
Intem measurements are more or less equally sensitive,
whereas Natem obviously possesses a lower sensitivity.
Natem represents the rotation thromboelastography
without activators only with re-calcification. Therefore, it
should be very similar to conventional TEG measurements.
Although fibrin-polymerization is relevant in dilutional coa-
gulopathy and Fibtem is a sensitive test, we decided not to
include the Fibtem results in our statistical analysis. Fibtem
has only one important parameter (MCF) which showed no
difference to the Extem-, Intem-, or Natem-MCF results and
had no additional value for our study since we statistically
compared significances of the test measurements with the
Fisher–Freeman–Halton test—so Fibtem would be the 17th
test measurement and would not change our results. Fur-
thermore, in 66% haemodilution with colloids, the Fibtem
was frequently technically not possible.
Interestingly, the ACT values of SONOCLOTTM and ROTEMTM
cannot be compared with each other. Our observation of a
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complex pattern of correlations between the different vari-
ables of the devices shows that the two different viscoelastic
methods introduce different ACT analyses. ROTEMTM-CT
describes the time between the beginning of pin rotation
until the pin begins to be impaired after fibrin–platelet
bonding has linked cup and pin.18 The vertical oscillation in
the sample of the SONOCLOTTM device is sensitive to viscosity
changes during initiation of coagulation. There are further
different activators: Celite for SONOCLOTTM, tissue thrombo-
plastin for Extem, partial thromboplastin for Intem, or no
activator for Natem. The two different procedures and the
different activators might explain the lack of statistic corre-
lation between the two tests.
A limitation of this in vitro study is the absence of physio-
logical reaction during haemodilution including recruitment
of additional resources of the coagulation system, changes
in plasma ions and acid–base balance, tissue damage, and
endothelial injury with their pro-coagulation properties, or
interaction between the volume expander and the endothelial
system. Further, the different colloid solutions have different
half times in vivo (HES.GEL), so that in vivo testing might gen-
erate different results compared with in vitro testing. In vivo
studies would be necessary to confirm our observations in
the clinical setting. Another limitating factor in our study is
the difference in the two HES products which are used in our
institution. They are from two different companies and
possess different molar substitution ratios (0.42 for the
balanced HES solution and 0.4 for the saline-based HES sol-
ution) and a different C2:C6 ratio (6:1 for the balanced HES sol-
ution and 9:1 for the saline-based HES solution).
In conclusion, haemodilution negatively affected blood
coagulation in vitro as measured by the viscoelastic devices
SONOCLOTTM and ROTEMTM, with less pronounced changes
when a balanced-electrolyte lactated Ringer’s solution is
used when compared with colloidal agents. Saline-based
gelatin solution did not show greater influence on haemo-
stasis than HES 130/0.4 (only a tendency in intergroup analy-
sis). There is no difference between the balanced HES
solution and the saline-based HES solution. Both viscoelastic
devices, ROTEMTM and SONOCLOTTM, are sensitive to changes
in blood coagulation during haemodilution, with MCF being
the most sensitive parameter in ROTEMTM analysis and ACT
in SONOCLOTTM analysis.
Conflict of interest
In the past 5 yr, D.R.S. has received honoraria or travel support
for consulting or lecturing from the following companies:
Abbott AG, Baar, Switzerland; Alliance Pharmaceutical Corp.,
San Diego, CA, USA; AstraZeneca AG, Zug, Switzerland; Bayer
(Schweiz) AG, Zu¨rich, Switzerland; B. Braun Melsungen AG,
Melsungen, Germany; CSL Behring GmbH, Hattersheim am
Main, Germany; Fresenius SE, Bad Homburg v.d.H., Germany;
Galenica AG, Bern, Switzerland (including Vifor SA, Villars-
sur-Glaˆne, Switzerland); GlaxoSmithKline GmbH & Co. KG,
Hamburg, Germany; Janssen-Cilag AG, Baar, Switzerland;
Novo Nordisk A/S, Bagsva¨rd, Denmark, Octapharma AG,
Lachen, Switzerland; Organon AG, Pfa¨ffikon/SZ, Switzerland;
and Roche Pharma (Schweiz) AG, Reinach, Switzerland.
Funding
Institute of Anesthesiology and Intensive Care, Kantonsspi-
tal, Lucerne, Switzerland.
Appendix
Table A1 Intergroup comparisons of 33% haemodilution with
different volume expanders (P,0.05 was considered statistically
significant). GEL, saline-based gelatin solution; RL,
balanced-electrolyte lactated Ringer’s solution; HESBAL,
balanced-electrolyte HES solution; HESSAL, saline-based HES
solution; ACT, activated clotting time; CFT, clot formation time;
CR, clot rate; CT, coagulation time; MCF, maximum clot firmness;
NS, not significant; PA, peak amplitude
RL GEL HESSAL HESBAL
ACT RL NS NS NS
GEL NS NS NS
HESSAL NS NS NS
HESBAL NS NS NS
CR RL 0.01 ,0.01 ,0.01
GEL 0.01 NS NS
HESSAL ,0.01 NS NS
HESBAL ,0.01 NS NS
TTP RL NS ,0.01 ,0.01
GEL NS NS NS
HESSAL ,0.01 NS NS
HESBAL ,0.01 NS NS
PA RL NS NS NS
GEL NS NS NS
HESSAL NS NS NS
HESBAL NS NS NS
Extem-CT RL NS NS 0.01
GEL NS NS 0.01
HESSAL NS NS NS
HESBAL 0.01 0.01 NS
Extem-CFT RL NS NS 0.01
GEL NS NS NS
HESSAL NS NS NS
HESBAL 0.01 NS NS
Extem-Alpha RL NS 0.03 ,0.01
GEL NS NS NS
HESSAL 0.03 NS NS
HESBAL ,0.01 NS NS
Extem-MCF RL NS 0.04 ,0.01
GEL NS NS NS
HESSAL 0.04 NS NS
HESBAL ,0.01 NS NS
Intem-CT RL NS NS NS
GEL NS NS NS
HESSAL NS NS NS
HESBAL NS NS NS
Intem-CFT RL NS 0.01 ,0.01
GEL NS NS NS
HESSAL 0.01 NS NS
HESBAL ,0.01 NS NS
Continued
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